Flu B Positive: What It Means and How to Treat It

A positive influenza B result means you are infected with one of the two main types of influenza virus that circulate in humans. Influenza B accounts for roughly a quarter of all flu cases worldwide on average, though in some seasons and locations it can cause the majority of infections. The practical upshot for you is straightforward: flu B is treated much the same way as flu A, with the same antivirals, the same supportive care, and a similar recovery timeline for most people. But there are real differences worth knowing about, from how accurate your test result is to which complications are more common with this type.

What a Positive Test Result Actually Means

Most people who test positive for flu B do so on a rapid diagnostic test, either at a clinic, pharmacy, or increasingly at home with a multiplex kit that checks for flu A, flu B, and COVID-19 simultaneously. These rapid tests are very good at ruling the flu in when they say “positive” — specificities run above 98% for clinical rapid tests, meaning false positives are rare.¹ So if your test says flu B, you almost certainly have it.

The bigger issue with rapid tests is the other direction: missing infections. Traditional rapid antigen tests catch only about half of flu B cases. Newer digital immunoassay devices do better, picking up around three-quarters. Molecular tests (sometimes called NAATs or rapid PCR) are the most accurate, catching over 95% of infections.¹ This means a negative rapid test does not reliably rule out flu B. If your doctor suspects flu based on symptoms and local circulation patterns, they may trust a clinical diagnosis even after a negative rapid result, or they may order a molecular test to confirm.

At-home multiplex tests have a specific quirk worth knowing about for flu B. One study evaluating a home rapid test found that while the overall sensitivity for flu B was around 65%, the positive predictive value was only about 33% — meaning two out of three people who tested positive for flu B at home in that study were actually false positives.² That low predictive value reflects how rare flu B was in the study population at the time, not a fundamental flaw in the test chemistry. When flu B is widely circulating in your area, the same test becomes much more reliable. The takeaway: if you get a positive flu B result on a home test during a season when flu B is not common locally, consider confirming with a clinical test before making major decisions.

One practical note on reading home tests: an analytical comparison of eight over-the-counter multiplex tests found that at low viral concentrations, tests that appeared negative at the start of the reading window sometimes turned positive by the end of it. The researchers recommended waiting the full incubation time stated in the instructions before concluding a test is negative.³

How Flu B Symptoms Differ from Flu A

Flu B and flu A cause the same core illness: fever, cough, sore throat, body aches, fatigue, and headache. A clinician generally cannot tell the two apart just by looking at you, which is why testing exists. But when researchers have compared large groups of patients, some patterns emerge.

Flu B tends to produce somewhat lower fevers than the more aggressive flu A subtypes. A study comparing adults with confirmed influenza A H1N1, A H3N2, and B found that the H3N2 group ran significantly higher temperatures and showed more severe markers of infection overall, while flu B patients tended to be younger and had milder fever and inflammatory markers.⁴ That said, flu B is not “mild flu.” It still causes serious illness and hospitalization, particularly in children and older adults.

The most consistent clinical difference is gastrointestinal. Nausea, stomach pain, and diarrhea show up more frequently with flu B than with either major flu A subtype.⁴ If your flu comes with a lot of gut symptoms alongside the usual respiratory misery, that is a soft clue that flu B may be the culprit — though it is far from diagnostic on its own.

Volunteer challenge studies, where healthy people are deliberately infected under controlled conditions, have shown that flu B infections produce fever in a somewhat lower proportion of infected individuals compared to flu A. Upper respiratory symptoms like congestion and sore throat were reported in roughly 60% of infected volunteers across influenza types, and viral shedding with flu B was a bit lower overall than with flu A subtypes.⁵

How Long You Are Contagious

Flu B viral shedding tends to be more variable in its timing than flu A. In one community-based study of naturally acquired infections, people with flu B started shedding the virus one to two days before symptoms appeared and continued for about six days after.⁶ Unlike flu A, where viral load tends to peak sharply and then decline, flu B shedding was more erratic over time, without a single clear peak. This means your contagiousness with flu B may not follow the neat “most contagious in the first two to three days” pattern that people often hear about.

Children shed virus for longer than adults — both before and after symptoms appear. In a household transmission study in Nicaragua, kids under six had the longest duration of shedding, followed by school-age children, with adults shedding for the shortest period.⁷ This is one reason why flu spreads so efficiently through schools and daycare centers.

The standard guidance — stay home for at least 24 hours after your fever breaks without the help of fever-reducing medication — still applies for flu B. But given the more variable shedding pattern, erring on the side of a longer isolation period is reasonable, particularly if you live with someone who is elderly, pregnant, or immunocompromised.

Antiviral Treatment

The same prescription antivirals that work against flu A work against flu B. The two most commonly used are oseltamivir (Tamiflu) and baloxavir marboxil (Xofluza). Both are effective, but they work through different mechanisms, and the practical differences matter.

Oseltamivir is a neuraminidase inhibitor, meaning it blocks the enzyme the virus uses to release new copies of itself from infected cells. It is taken twice daily for five days. Studies of oseltamivir’s effect on viral shedding show that it shortens shedding duration and reduces the total amount of virus released, though the response varies considerably between individuals — in roughly 20–40% of treated volunteers, oseltamivir had no measurable impact on how long they shed virus.⁸ It works best when started within 48 hours of symptom onset, though for high-risk patients it may still be worth starting later.

Baloxavir works differently — it is a cap-dependent endonuclease inhibitor that blocks the virus from copying its genetic material inside your cells. It was first approved in Japan in 2018 and is taken as a single oral dose, which is a significant convenience advantage over oseltamivir’s five-day course.⁹ Modeling based on clinical trial data suggests baloxavir reduces viral load more rapidly: within one day of treatment, viral load dropped by an estimated 84% with baloxavir compared to 56% with oseltamivir and 39% with no treatment.¹⁰ That faster viral knockdown could translate to a shorter window of contagiousness, though more real-world data is still accumulating.

One consideration specific to flu B: resistance to neuraminidase inhibitors like oseltamivir has stayed low overall, and the majority of documented resistance occurs in flu A, particularly in immunocompromised patients on prolonged treatment courses. Resistance in flu B is seen less frequently.¹¹ So for a typical flu B infection, oseltamivir remains a reliable option.

Not every flu B case requires antiviral treatment. Antivirals are most important for people at higher risk of complications: young children, adults over 65, pregnant women, and people with chronic medical conditions. For an otherwise healthy adult with uncomplicated flu B, antivirals shorten illness by roughly a day and reduce severity modestly. Whether that is worth a prescription is a conversation between you and your doctor, often hinging on how early you can start treatment and how sick you feel.

Managing Symptoms at Home

Whether or not you take an antiviral, symptomatic treatment is the backbone of flu recovery. Over-the-counter pain relievers and fever reducers — acetaminophen (paracetamol) and ibuprofen — are both effective and, at standard doses, equally safe for relieving the aches and fever of flu. There is no evidence that one works better than the other for cold and flu symptoms.¹² Aspirin should not be given to children or teenagers with flu due to the risk of Reye’s syndrome.

Beyond medications, the usual advice applies: stay hydrated, rest, and do not push yourself to return to normal activities too quickly. The gastrointestinal symptoms that are more common with flu B make hydration especially important — if you are dealing with nausea and diarrhea on top of fever and sweating, you lose fluids faster than you realize.

For supplements, the evidence is modest. Oral zinc may reduce the length and severity of upper respiratory infections, and regular vitamin C supplementation slightly reduces the duration of colds, though the effect is small.¹³ Neither is a substitute for rest and proper hydration, but they are unlikely to cause harm at standard doses.

Complications That Are More Common with Flu B

One complication is particularly associated with influenza B in children: benign acute childhood myositis. This is a sudden, sometimes alarming onset of severe calf pain that makes a child reluctant or unable to walk. It typically appears a few days after the initial flu symptoms have started to improve. In one study of children with confirmed flu B, about 9% developed significant calf pain with gait disturbances. Blood tests show sharply elevated creatine kinase, a marker of muscle breakdown, but the condition is self-limiting — symptoms resolve and muscle enzyme levels return to normal.¹⁴¹⁵ If your child suddenly cannot walk properly a few days into the flu, it is worth calling your pediatrician, but this is generally not a dangerous complication.

For adults, particularly older adults and those with underlying heart conditions, the more serious concern is cardiovascular complications. A study of patients hospitalized with influenza-related pneumonia found that about a quarter developed at least one cardiovascular event — including heart failure exacerbation, heart attack, or arrhythmia — and that these events were linked to a more than threefold increase in 30-day mortality. Early antiviral treatment was associated with lower cardiovascular risk.¹⁶ While that study included both flu A and flu B patients, it underscores why antivirals are recommended promptly for anyone hospitalized with influenza, regardless of type.

Who Faces the Highest Risk

Globally, flu B hits children especially hard. Estimates suggest the virus causes roughly eight million lower respiratory tract infections and over a million hospitalizations annually, with the burden disproportionately falling on children aged 0 to 18.¹⁷ This is partly because children have had fewer lifetime exposures and therefore less accumulated immunity.

Pregnant women are another high-risk group. Pregnancy naturally alters the immune system and lung capacity, raising the risk of severe pneumonia and respiratory failure from any influenza infection. Early antiviral therapy is recommended even if the 48-hour treatment window has passed.¹⁸ Similarly, immunosuppressed patients — particularly those who have undergone stem cell or lung transplants or who are receiving chemotherapy — face prolonged and more severe infections. For these patients, antivirals may help even when started well beyond the usual 48-hour window.¹⁸

Protecting Household Members

If one person in the household tests positive for flu B, there is strong evidence that prophylactic antivirals can prevent the rest of the family from getting sick. A randomized trial of oseltamivir given to household contacts of flu-positive patients found 89% protective efficacy against developing clinical influenza, and viral shedding was also suppressed in the contacts taking the drug.¹⁹ A separate trial of inhaled zanamivir found that only 4% of families in the treatment group had a secondary case, compared to 19% in the placebo group, with the drug effective against both flu A and flu B.²⁰

Post-exposure prophylaxis is not routinely prescribed for every household, but it makes particular sense when someone in the home is at high risk for complications. If you live with an elderly parent, a pregnant partner, or a child with asthma, asking your doctor about prophylactic antivirals for the household is a reasonable step.

Can You Get Flu B Again

Yes, and probably sooner than you would expect. A long-running study that tracked flu B reinfections found that protection from a prior infection waned steadily: it was about 65% effective at preventing reinfection after two to three years, dropped to 46% after four to five years, and offered no measurable protection after seven years.²¹ This fading immunity is one reason flu B continues to circulate year after year and why annual vaccination matters even if you had flu B recently.

Vaccination itself produces variable immune responses to flu B strains. Studies have found that vaccines sometimes generate less robust antibody responses against the B component compared to flu A components.²² This is one of the reasons flu B can cause substantial outbreaks even in well-vaccinated populations. It is still worth getting vaccinated — the vaccine reduces your odds of severe illness even when the antibody response to the B component is imperfect.

Why Flu B Often Peaks Late in the Season

If you tested positive for flu B in February or March, you are in good company. In the Northern Hemisphere, flu B epidemics tend to peak later in the flu season than flu A — around mid-February on average, compared to mid-to-late January for flu A subtypes.²³ In the tropics, the timing gap between flu A and B peaks is even more pronounced, with peaks separated by three months or more in the majority of seasons.²⁴

This late-season tendency has a practical consequence: people sometimes let their guard down or assume flu season is over by late winter. Flu B can cause a second wave that catches the public off guard. It also means some people who skipped their flu shot early in the season might still benefit from getting one later, particularly if flu B activity has not yet peaked in their area.

The Two Lineages and Why One May Have Disappeared

Until recently, flu B circulated as two distinct genetic lineages, called Victoria and Yamagata, that split from each other in the 1970s and co-circulated globally for decades.²⁵ The two lineages are different enough that infection with one does not reliably protect you against the other, which is why quadrivalent flu vaccines were developed to include a strain from each lineage.

Something unusual happened during the COVID-19 pandemic: the Yamagata lineage has not been detected in surveillance samples since around 2020. The leading explanation is that the public health measures used to control SARS-CoV-2 — masking, distancing, travel restrictions — also suppressed influenza circulation enough to push the less fit lineage below the threshold of sustainable transmission. Research suggests that Yamagata had slower antigenic evolution and weaker positive selection pressure compared to Victoria, which may have made it more vulnerable to extinction during a period of reduced human-to-human contact.²⁶

If the Yamagata lineage is truly gone, flu B is now a single-lineage virus. This has already begun shifting vaccine strategy — many manufacturers are moving back to trivalent vaccines that include only a Victoria-lineage B strain. For you as a patient, this means that if you test positive for flu B today, the virus is almost certainly a Victoria-lineage strain. From a treatment standpoint, the lineage does not change what you do — antivirals and supportive care work the same either way. But it is worth noting that the two lineages did differ biologically. Victoria strains induced a stronger interferon response in human nasal cells compared to Yamagata, though both lineages replicated to similar levels.²⁷ Whether a single-lineage future makes flu B more or less predictable from a public health perspective remains an open question.

1
PubMed. Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Infection Compared With Reverse Transcriptase Polymerase Chain Reaction: A Systematic Review and Meta-analysis
2
PubMed Central. Diagnostic Accuracy of an At-Home, Rapid Self-test for Influenza: Prospective Comparative Accuracy Study
3
PubMed Central. Analytical comparison of over-the-counter multiplex tests for influenza A, influenza B, and SARS-CoV-2
4
PubMed. Differences in clinical features between influenza A H1N1, A H3N2, and B in adult patients
5
American Journal of Epidemiology. Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies
6
The Journal of Infectious Diseases. Viral Shedding and Clinical Illness in Naturally Acquired Influenza Virus Infections
7
PubMed Central. The Timeline of Influenza Virus Shedding in Children and Adults in a Household Transmission Study of Influenza in Managua, Nicaragua
8
PubMed Central. Impact of Oseltamivir Treatment on Influenza A and B Virus Dynamics in Human Volunteers
9
PubMed. Baloxavir: First Global Approval
10
Nature Communications. Modeling mitigation of influenza epidemics by baloxavir
11
PubMed Central. Influenza and antiviral resistance: an overview
12
PubMed. Efficacy and safety of over-the-counter analgesics in the treatment of common cold and flu
13
PubMed Central. Prevention and Treatment of Influenza, Influenza-Like Illness, and Common Cold by Herbal, Complementary, and Natural Therapies
14
PubMed Central. Analysis of Clinical Manifestations and Laboratory Findings in Children with Influenza B-Associated Myositis: A Single Center Study
15
PubMed Central. Benign acute childhood myositis complicating influenza B infection in a boy with idiopathic nephrotic syndrome
16
PubMed Central. Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia
17
The Lancet Infectious Diseases. Flu B Positive: What It Means and How to Treat It (Excerpt / Context)
18
Critical Care Medicine. H1N1 novel influenza A in pregnant and immunocompromised patients
19
JAMA. Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial
20
New England Journal of Medicine. Inhaled zanamivir for the prevention of influenza in families
21
American Journal of Epidemiology. INFLUENZA B VIRUS REINFECTION
22
PubMed Central. Seasonal influenza vaccines: Variability of immune responses to B lineage viruses.
23
PLoS ONE. Global Patterns in Seasonal Activity of Influenza A/H3N2, A/H1N1, and B from 1997 to 2005: Viral Coexistence and Latitudinal Gradients
24
PLoS ONE. Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?
25
PubMed Central. Divergent evolutionary trajectories of influenza B viruses underlie their contemporaneous epidemic activity
26
Nature Communications. Unraveling the mechanism behind the probable extinction of the B/Yamagata lineage of influenza B viruses
27
PubMed Central. The Influenza B Virus Victoria and Yamagata Lineages Display Distinct Cell Tropism and Infection-Induced Host Gene Expression in Human Nasal Epithelial Cell Cultures